HK1183021A1 - 用於檢測神經障礙的成像劑 - Google Patents

用於檢測神經障礙的成像劑

Info

Publication number
HK1183021A1
HK1183021A1 HK13110300.9A HK13110300A HK1183021A1 HK 1183021 A1 HK1183021 A1 HK 1183021A1 HK 13110300 A HK13110300 A HK 13110300A HK 1183021 A1 HK1183021 A1 HK 1183021A1
Authority
HK
Hong Kong
Prior art keywords
neurological disorders
imaging agents
detecting neurological
detecting
imaging
Prior art date
Application number
HK13110300.9A
Other languages
English (en)
Inventor
Daniel Kurt Cashion
Gang Chen
Dhanalakshmi Kasi
Hartmuth C Kolb
Changhui Liu
Anjana Sinha
Anna Katrin Szardenings
Eric Wang
Chul Yu
Wei Zhang
Umesh B Gangadharmath
Joseph C Walsh
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/661,777 external-priority patent/US8491869B2/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1183021A1 publication Critical patent/HK1183021A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK13110300.9A 2010-03-23 2013-09-04 用於檢測神經障礙的成像劑 HK1183021A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/661,777 US8491869B2 (en) 2009-03-23 2010-03-23 Imaging agents for detecting neurological disorders
US13/035,405 US8691187B2 (en) 2009-03-23 2011-02-25 Imaging agents for detecting neurological disorders
PCT/US2011/029368 WO2011119565A1 (en) 2010-03-23 2011-03-22 Imaging agents for detecting neurological disorders

Publications (1)

Publication Number Publication Date
HK1183021A1 true HK1183021A1 (zh) 2013-12-13

Family

ID=44063488

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13110300.9A HK1183021A1 (zh) 2010-03-23 2013-09-04 用於檢測神經障礙的成像劑

Country Status (9)

Country Link
US (1) US8691187B2 (zh)
EP (1) EP2550255B1 (zh)
JP (1) JP5684893B2 (zh)
KR (1) KR101447795B1 (zh)
CN (1) CN102985411B (zh)
CA (1) CA2794004C (zh)
ES (1) ES2578228T3 (zh)
HK (1) HK1183021A1 (zh)
WO (1) WO2011119565A1 (zh)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US10639608B2 (en) 2010-04-08 2020-05-05 Siemens Medical Solutions Usa, Inc. System, device and method for preparing tracers and transferring materials during radiosynthesis
JP6245981B2 (ja) 2010-04-08 2017-12-13 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッドＳｉｅｍｅｎｓ Ｍｅｄｉｃａｌ Ｓｏｌｕｔｉｏｎｓ ＵＳＡ，Ｉｎｃ． 含水有機溶媒中の１８ｆ−標識化トレーサーの合成
DK2634177T3 (en) * 2010-10-29 2016-08-15 Clino Ltd TAU IMAGE SOUND
JP2013542993A (ja) * 2010-11-19 2013-11-28 ジーイー・ヘルスケア・リミテッド 初期タウオパシーの診断のためのチウの検出におけるシアニン色素の使用
JP5976206B2 (ja) * 2012-05-22 2016-08-23 イーライ リリー アンド カンパニー 神経機能障害を検出するための造影剤
WO2013181075A1 (en) * 2012-05-29 2013-12-05 Merck Sharp & Dohme Corp. Isotopically labeled biaryl urea compounds
WO2014097474A1 (ja) 2012-12-21 2014-06-26 独立行政法人放射線医学総合研究所 脳内に蓄積したタウタンパク質をイメージングするための新規化合物
CA2900300A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4
CN103172637B (zh) * 2013-03-13 2015-05-27 上海大学 嘧啶并[1,2-a]苯并咪唑类化合物及其制备方法
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN103242229B (zh) * 2013-04-10 2015-09-02 江苏华益科技有限公司 一种用于神经退行性疾病领域的pet显像剂thk523前体的合成方法
CN105229009B (zh) * 2013-05-23 2017-09-29 豪夫迈·罗氏有限公司 作为成像剂的2‑苯基咪唑并[1,2‑a]嘧啶
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
JP6182668B2 (ja) * 2013-09-26 2017-08-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 画像化ツールとしてのイミダゾ［１，２−ａ］ピリジン−７−アミン
DK3055308T3 (en) * 2013-10-08 2018-01-22 Hoffmann La Roche Diazacarbazole derivatives as tau PET ligands
MX2016005233A (es) * 2013-10-22 2017-01-05 Clino Ltd Sonda de formacion de imagenes para tau.
CN103614135B (zh) * 2013-11-29 2015-07-01 安徽大学 一种双光子荧光探针及其制备方法和用途
CN106029666B (zh) 2013-12-19 2018-05-18 诺华股份有限公司 作为原生动物蛋白酶体抑制剂用于治疗寄生虫疾病例如利什曼病的[1,2,4]三唑并[1,5-a]嘧啶衍生物
WO2015110263A1 (en) * 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
PT3143011T (pt) 2014-05-13 2021-04-26 Hoffmann La Roche Compostos heterocíclicos deuterados e a sua utilização como agentes de imagiologia
MX2017002703A (es) 2014-08-29 2018-01-16 Chdi Foundation Inc Sondas para la proyección de imagen de la proteína huntingtina.
KR20170047341A (ko) 2014-08-29 2017-05-04 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴 단백질을 영상화하기 위한 프로브
US10080812B2 (en) 2015-03-04 2018-09-25 Kyoto University Radioactive iodine labeled pyrido[1,2-a]benzoimidazole derivative compound
CA2980159A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
JP6779899B2 (ja) 2015-03-18 2020-11-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｎｆ阻害剤として有用なヘテロ環式化合物
US10308652B2 (en) 2015-03-18 2019-06-04 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of TNF
US9856253B2 (en) 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
WO2016168638A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
EP3118202A1 (en) 2015-07-15 2017-01-18 AC Immune S.A. Dihydropyridopyrrole derivatives as tau-pet-ligands
EP3322707A1 (en) * 2015-07-15 2018-05-23 AC Immune SA Novel imaging compounds
CA2994703A1 (en) 2015-08-03 2017-02-09 Bristol-Myers Squibb Company Cyclic compounds useful as modulators of tnf alpha
TW201707726A (zh) * 2015-08-19 2017-03-01 國立大學法人京都大學 放射性鹵素標誌吡啶并［１，２－ａ］苯并咪唑衍生物化合物
JP2018531978A (ja) 2015-11-13 2018-11-01 イーライ リリー アンド カンパニー タウイメージングのための新規化合物
CN106008374B (zh) * 2016-06-07 2018-07-27 四川大学 吡嗪类化合物及其在医药上的用途
MY196981A (en) 2016-07-22 2023-05-16 Ac Immune Sa Compounds for imaging tau protein aggregates
JP7059270B2 (ja) 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
FR3054445B1 (fr) * 2016-07-26 2019-07-05 Laboratoires Cyclopharma Synthese d'une composition d'agent radioactif
EP3510031B1 (en) 2016-09-09 2020-12-02 H. Hoffnabb-La Roche Ag Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole
FR3056592B1 (fr) * 2016-09-26 2018-11-16 Centre National De La Recherche Scientifique Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives
WO2018055316A1 (fr) * 2016-09-26 2018-03-29 Centre National De La Recherche Scientifique Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives
KR102570992B1 (ko) * 2016-11-01 2023-08-28 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
JP6955347B2 (ja) * 2017-02-28 2021-10-27 日本メジフィジックス株式会社 フルテメタモルの製造方法
JP7008299B2 (ja) * 2017-03-10 2022-01-25 国立大学法人滋賀医科大学 神経難病の画像診断薬及び体外診断薬
TW201922721A (zh) * 2017-09-07 2019-06-16 英商葛蘭素史克智慧財產發展有限公司 化學化合物
CN108047145B (zh) * 2017-11-17 2020-12-15 北京师范大学 与Tau蛋白具有亲和力的2-芳基喹喔啉类化合物及其制备方法与应用
JP7269948B2 (ja) 2017-11-28 2023-05-09 エフ． ホフマン－ラ ロシュ アーゲー 新規複素環式化合物
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
WO2019145292A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
IL278579B1 (en) * 2018-05-09 2024-05-01 Aprinoia Therapeutics Inc Heteroaryl compounds and uses thereof
AU2020267664B2 (en) 2019-05-09 2023-04-27 F. Hoffmann-La Roche Ag Synthesis of labeled imidazo[1,2-A]pyrimidines
CN112010846A (zh) * 2019-05-30 2020-12-01 四川大学华西医院 一种吡啶衍生物及其制备方法和用途
JP2022540935A (ja) 2019-07-17 2022-09-20 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化化合物および関連する使用方法
CN114650994A (zh) 2019-09-12 2022-06-21 豪夫迈·罗氏有限公司 放射性标记的化合物
CN112525868B (zh) * 2019-09-19 2022-04-22 吉林大学 喹哪啶红及其衍生物在制备检测淀粉样纤维的试剂盒中的应用
WO2021097243A1 (en) 2019-11-13 2021-05-20 Aprinoia Therapeutics Inc. Compounds for degrading tau protein aggregates and uses thereof
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR102369838B1 (ko) * 2020-04-16 2022-03-04 연세대학교 산학협력단 퀴놀린 유도체를 유효성분으로 포함하는 성상교세포증 관련 질환의 병변 경계부 검출용 조영제 조성물
MX2022013838A (es) 2020-05-04 2023-02-22 Amgen Inc Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso.
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
EP4175719A1 (en) 2020-07-02 2023-05-10 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
CA3237199A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5871894A (en) 1992-12-21 1994-07-19 Mallinckrodt Medical, Inc. Polyhydric phenol compounds
WO1995007922A1 (en) * 1993-09-17 1995-03-23 Smithkline Beecham Corporation Drug binding protein
JP2000510816A (ja) 1995-10-17 2000-08-22 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２の検出法
JPH09165378A (ja) 1995-12-15 1997-06-24 Seitai Kinou Kenkyusho:Kk Ｎ１−［１８ｆ］フルオロベンジル複素環化合物およびそれらの製造法
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
EP1381604B1 (en) 2001-04-23 2006-12-27 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
WO2003018070A1 (en) * 2001-08-27 2003-03-06 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
JP2006513996A (ja) * 2002-10-24 2006-04-27 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体結合用トレーサーとしてのアルキン誘導体
WO2004043496A1 (de) 2002-11-11 2004-05-27 Austria Wirtschaftsservice Gesellschaft M.B.H. Fluor-18-markierte fluorchinolone
GB0229686D0 (en) 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles
EP1610781A1 (en) 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of tipranavir and a further antiretroviral compound
EP1655287A1 (en) 2003-08-13 2006-05-10 BF Research Institute, Inc. Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change
JP2006100537A (ja) 2004-09-29 2006-04-13 Konica Minolta Holdings Inc 有機エレクトロルミネッセンス素子、照明装置及び表示装置
US20060110787A1 (en) * 2004-11-19 2006-05-25 The Board Trustees Of The University Of Arkansas Use of fluorine-18-labeled fluoroquinolone antibiotics for diagnosing and monitoring bacterial infection
US8192717B2 (en) 2004-11-26 2012-06-05 Nagasaki University Composition for diagnosing amyloid-related diseases
WO2006116736A2 (en) 2005-04-27 2006-11-02 Siemens Medical Solutions Usa, Inc. A method for the preparation of imaging probes using click chemistry
CA2616397A1 (en) 2005-08-03 2007-02-08 Centre For Addiction And Mental Health Diagnosis and treatment of mood disorders
GB0523506D0 (en) 2005-11-18 2005-12-28 Hammersmith Imanet Ltd Novel in vivo imaging compounds
EP1956013B1 (en) 2005-11-30 2016-04-13 Fujifilm RI Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
AR059356A1 (es) 2006-02-14 2008-03-26 Astrazeneca Ab Nuevos radioligandos
JP2007223952A (ja) 2006-02-23 2007-09-06 Tohoku Univ アミロイドβ蛋白が蓄積する疾患の画像診断プローブ
US7700616B2 (en) * 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
WO2008027162A2 (en) 2006-08-28 2008-03-06 The Trustees Of The University Of Pennsylvania 129xe biosensors and their use
US7678819B2 (en) 2006-12-07 2010-03-16 The Trustees Of The University Of Pennsylvania Acetylene derivatives and their use for binding and imaging amyloid plaques
EP1944281A1 (en) 2007-01-09 2008-07-16 Technische Universität München 18F-labeled compounds, method for the preparation and use thereof
BRPI0702640A (pt) 2007-01-10 2008-08-26 Comissao Nac Energia Nuclear processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos
WO2008124812A1 (en) 2007-04-10 2008-10-16 The Trustees Of The University Of Pennsylvania Phen-naphthalene and phen-quinoline derivatives and their use for binding and imaging amyloid plaques
JP2010524965A (ja) 2007-04-19 2010-07-22 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ジフェニル−ヘテロアリール誘導体並びにアミロイド斑への結合及び画像化のためのその使用
WO2008132454A1 (en) 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
US8942164B2 (en) 2007-10-22 2015-01-27 Texas Instruments Incorporated Differential CQI for OFDMA systems
JP5322180B2 (ja) 2007-07-04 2013-10-23 国立大学法人東北大学 フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
WO2009045535A2 (en) 2007-10-04 2009-04-09 Sloan-Kettering Institute For Cancer Research Fluorine-18 derivative of dasatinib and uses thereof
US8318132B2 (en) 2008-02-14 2012-11-27 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological dysfunction
EP2323697A2 (en) 2008-07-24 2011-05-25 Siemens Medical Solutions USA, Inc. Imaging agents useful for identifying ad pathology
JP2012051804A (ja) 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤
EP2218464A1 (en) 2009-02-11 2010-08-18 Technische Universität München Compounds for non-invasive measurement of aggregates of amyloid peptides
CN103739605B (zh) 2009-03-23 2016-08-17 伊莱利利公司 用于检测神经障碍的显像剂

Also Published As

Publication number Publication date
EP2550255B1 (en) 2016-04-27
CN102985411A (zh) 2013-03-20
CN102985411B (zh) 2016-02-10
US8691187B2 (en) 2014-04-08
EP2550255A1 (en) 2013-01-30
US20110182812A1 (en) 2011-07-28
ES2578228T3 (es) 2016-07-21
CA2794004C (en) 2016-04-26
CA2794004A1 (en) 2011-09-29
KR20130020781A (ko) 2013-02-28
JP5684893B2 (ja) 2015-03-18
KR101447795B1 (ko) 2014-10-06
JP2013522365A (ja) 2013-06-13
WO2011119565A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
HK1183021A1 (zh) 用於檢測神經障礙的成像劑
LT2997901T (lt) Vaizdo gavimo zondas
ZA201300435B (en) Apparatus for disease detection
EP2434928A4 (en) DEVICE FOR INCREASED TRAVEL COMFORT
HRP20220401T3 (hr) Nova vizualizacijska sredstva za detektiranje neurološke disfunkcije
EP2604176A4 (en) IMAGING DEVICE
EP2624540A4 (en) IMAGING DEVICE
EP2626002A4 (en) IMAGING DEVICE
SG10201706428XA (en) Charge-balanced imaging agents
EP2698668A4 (en) IMAGING DEVICE
EP2750374A4 (en) IMAGING DEVICE
EP2629504A4 (en) IMAGING DEVICE
EP2719320A4 (en) IMAGING DEVICE
EP2636359A4 (en) IMAGING DEVICE
EP2719319A4 (en) IMAGING DEVICE
EP2735262A4 (en) IMAGING DEVICE
EP2725802A4 (en) IMAGING DEVICE
GB2482066B (en) Imaging
EP2646580A4 (en) METHOD FOR DETECTING NEURODEEGENERATIVE ILLNESSES AND SUFFERING
EP2624541A4 (en) IMAGING DEVICE
EP2704416A4 (en) IMAGING DEVICE
EP2715428A4 (en) IMAGING DEVICE
EP2715444A4 (en) IMAGING DEVICE
EP2800377A4 (en) IMAGING DEVICE
EP2667591A4 (en) SOLID STATE IMAGE DEVICE